Advanced Cell Diagnostics Inc. has launched an in situ RNA detection technology that it says is more sensitive than protein-based technologies and more specific than real-time PCR. The company is focusing on clinical development markets while developing the technology for in vitro diagnostics.

Traditional in situ detection technologies use antibodies to detect proteins associated with disease. But in many cases, a protein's expression is too low to be detected. In some cases, antibodies cannot be developed for the target protein.